JPMorgan Chase & Co. Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX) had its target price increased by JPMorgan Chase & Co. from $116.00 to $121.00 in a research note released on Monday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other analysts have also issued reports on BNTX. HC Wainwright restated a “buy” rating and set a $136.00 target price on shares of BioNTech in a research report on Monday, September 8th. Wells Fargo & Company set a $150.00 target price on shares of BioNTech and gave the company an “overweight” rating in a research report on Tuesday, August 5th. The Goldman Sachs Group started coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a “neutral” rating and a $110.00 target price for the company. Leerink Partners set a $112.00 target price on shares of BioNTech in a research report on Monday, June 2nd. Finally, Morgan Stanley boosted their target price on shares of BioNTech from $132.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.56.

BioNTech Stock Performance

Shares of BNTX stock opened at $98.72 on Monday. The company has a 50 day moving average price of $107.10 and a 200-day moving average price of $103.31. BioNTech has a 52 week low of $81.20 and a 52 week high of $129.27. The firm has a market capitalization of $23.73 billion, a PE ratio of -61.70 and a beta of 1.39. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. During the same quarter in the prior year, the firm earned ($3.36) earnings per share. The business’s revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that BioNTech will post -3.88 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Several large investors have recently added to or reduced their stakes in BNTX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in BioNTech by 19.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 221,080 shares of the company’s stock valued at $25,192,000 after purchasing an additional 36,746 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in BioNTech during the fourth quarter valued at approximately $235,000. Jefferies Financial Group Inc. purchased a new position in shares of BioNTech in the fourth quarter worth $570,000. Probity Advisors Inc. lifted its holdings in shares of BioNTech by 8.5% in the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock worth $224,000 after buying an additional 154 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in shares of BioNTech in the fourth quarter worth $238,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.